Izvorni znanstveni članak
https://doi.org/10.20471/acc.2024.63.03-04.03
Transient Hypophosphatemia as Possible Adverse Outcome after Iron Deficiency Anemia Treatment with Ferric Carboxymaltose – Single Center Experience
Nikolina Brkić
; Department of Transfusion medicine, General Hospital Vinkovci, Vinkovci, Croatia; Faculty of Medicine, University of Osijek, Osijek, Croatia
*
Ivana Vučinić Ljubičić
; Hematology and Oncology Department, “Dr. Josip Benčević” General Hospital, Slavonski Brod, Croatia
Hrvoje Holik
; Hematology and Oncology Department, “Dr. Josip Benčević” General Hospital, Slavonski Brod, Croatia
Božena Coha
; Hematology and Oncology Department, “Dr. Josip Benčević” General Hospital, Slavonski Brod, Croatia
* Dopisni autor.
Sažetak
The aim of this study was to determine the frequency of hypophosphatemia in
female patients with iron deficiency anemia (IDA) treated parenterally with ferric carboxymaltose
(FCM). Thirty-two female patients examined for IDA at the Hematology and Oncology Department
of one General Hospital were included in the study. The inclusion criteria were hemoglobin <110 g/L,
transferrin saturation <50%, ferritin <30 ng/mL, and ineffective oral iron therapy. The hemoglobin
values were significantly increased 6 weeks after therapy in comparison with initial values. The onset
of the asymptomatic hypophosphatemia was observed in 17 of 32 patients two weeks after the FCM
therapy. Only one of 32 patients had severe asymptomatic hypophosphatemia (serum phosphate <0.3
mmol/L). Prolonged hypophosphatemia (6 weeks after FCM therapy) was observed in five of 32
patients, of which only one patient had initial hypophosphatemia. The difference between the phosphate
values measured two weeks after the FCM therapy and the phosphate values at the first and last
follow-up was statistically significant. Serum phosphate values should be routinely measured before
and after parenteral FCM therapy.
Ključne riječi
Ferric carboxymaltose; Hypophosphatemia; Iron deficiency anemia
Hrčak ID:
333031
URI
Datum izdavanja:
31.12.2024.
Posjeta: 825 *